Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4453943 | 1.00 | AURKA (0.65) | AURKAABCG2MAOASMN1; SMN2MAPT | |
| SCHEMBL4455661 | 0.90 | AURKA (0.69) | AURKAABCG2MAOAMAPTMAOB | |
| SCHEMBL4455655 | 0.90 | AURKA (0.69) | AURKAABCG2MAOAMAPTMAOB | |
| SCHEMBL4448152 | 0.88 | SLC5A1 (0.48) | AURKAABCG2MAOASMN1; SMN2MAPT | |
| SCHEMBL4448153 | 0.88 | SLC5A1 (0.48) | AURKAABCG2MAOASMN1; SMN2MAPT | |
| SCHEMBL4447938 | 0.84 | AURKA (0.84) | AURKAABCG2MAOAMAPTCYP1A1 | |
| SCHEMBL4447934 | 0.84 | AURKA (0.84) | AURKAABCG2MAOAMAPTCYP1A1 | |
| SCHEMBL979440 | 0.82 | ABCG2 (0.75) | AURKAABCG2MAOAMAPTLMNA | |
| SCHEMBL979442 | 0.82 | ABCG2 (0.75) | AURKAABCG2MAOAMAPTLMNA | |
| SCHEMBL4456467 | 0.81 | ABCG2 (0.84) | AURKAABCG2MAOAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | claimed |
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | disclosed |
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | disclosed |
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | UNIVERSITE JOSEPH FOURIER GRENOBLE I (FR) | 2009-07-16 | — | — | US | disclosed |
| WO-2007083060-A2 | NOVEL CHALCONE DERIVATIVES WITH ANTIMITOTIC ACTIVITY | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182058-A1 | Novel Chalcone Derivatives With Antimitotic Activity | ABCE1, CCNE1, FOXM1 | AURKA 747/4885ABCG2 38/4885MAOA 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.